---
title: "Weekly Recap | DexCom -3.06%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300187913.md"
description: "DexCom (DXCM) fell 3.06% this week to close at $86.62, underperforming the S&P 500, which rose 1.21%, by about 4.27 percentage points. The stock faded after an early push higher: Monday and Tuesday saw it reach $90.385, but Thursday and Friday both closed lower, with Friday settling at $86.62. The close sits below the 20-day moving average of $87.577 but above the 60-day average of $83.284. Weekly amplitude was 4.53% and average daily volume was 3.70m shares, 8."
datetime: "2026-09-26T06:17:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300187913.md)
  - [en](https://longbridge.com/en/news/300187913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300187913.md)
generator: "portal-rs"
---

# Weekly Recap | DexCom -3.06%, most brokers rate it buy

## The Week

DexCom (DXCM) fell 3.06% this week to close at $86.62, underperforming the S&P 500, which rose 1.21%, by about 4.27 percentage points. The stock faded after an early push higher: Monday and Tuesday saw it reach $90.385, but Thursday and Friday both closed lower, with Friday settling at $86.62. The close sits below the 20-day moving average of $87.577 but above the 60-day average of $83.284. Weekly amplitude was 4.53% and average daily volume was 3.70m shares, 8.03% below its median, suggesting a quiet tape.

## Key Events

No company-specific earnings or product news surfaced this week. On 22 September a market commentary placed DexCom within a broader discussion of digital ecosystem moats, without touching operating details. On 23 September American Diversified Holdings unit GlucoGuard published an investor deck for FDA research funding, a competitive-landscape development. On 24 September two updates arrived: one noted DexCom underperformed peers on Wednesday, matching the stock’s midweek slide, and another disclosed that Andra AP fonden sold 72,300 shares. Taken together, the week lacked internal catalysts and leaned on external positioning moves.

## Analyst Ratings

Coverage stands at 29 firms: 22 rate it buy, 3 overweight, 3 hold, and 1 no opinion, with no underweight or sell. The consensus rating is strong buy and the consensus target is $94.48, about 9.07% above the $86.62 spot. Target prices range from $79 to $115, a wide spread that points to divided views on valuation. DexCom ranks 4th among 142 names in its medical-device industry. The sell-side tilt remains constructive, though the wide target band captures real disagreement.

## The Week Ahead

DexCom has no earnings on the calendar. Next week is heavy on US macro data. The Dallas Fed manufacturing index arrives on 28 September, prior 11.6. On 29 September investors get FHFA house prices, Case Shiller 20-city index, JOLTS job openings (prior 7.271m, forecast 7.24m) and consumer confidence (prior 89.4, forecast 90). For medical-device names, a soft JOLTS or confidence print could weigh on risk appetite. More directly, the question is whether DexCom can find support near the $86 level and the 60-day average.

## In Short

This week’s decline sat alongside quiet institutional repositioning and a broader market contrast. Analyst views remain one-sidedly strong buy, with the consensus target about 9% above spot, yet the week also brought a shareholder sale and underperformance versus peers. The latest session’s flow skewed toward net selling in smaller orders while large-lot buying was modest. Valuation at roughly 32.7x earnings and 12.47x book is not cheap, though not extreme for a growth name. The watch item going forward is whether macro prints next week shift risk appetite and whether the stock can hold around its 60-day average.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [DXCM.US](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

- [U.S. RESEARCH ROUNDUP- Amrize, Dexcom, Lennar](https://longbridge.com/en/news/300660107.md)
- [Earnings Preview: What To Expect From DexCom's Report](https://longbridge.com/en/news/291792429.md)
- [‘SpaceX Stock Is in the Danger Zone,’ Says Investor](https://longbridge.com/en/news/301052732.md)
- [History Says Infrastructure Booms Create Winners and Losers. Here Are 3 AI Cloud Stocks to Watch.](https://longbridge.com/en/news/301060298.md)
- [Seagate vs. Western Digital vs. Toshiba: The AI Storage War Is Getting Serious](https://longbridge.com/en/news/301054654.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**